An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

被引:68
|
作者
Dziadziuszko, Rafal [1 ]
Le, Anh T. [2 ]
Wrona, Anna [1 ]
Jassem, Jacek [1 ]
Camidge, D. Ross [2 ]
Varella-Garcia, Marileila [2 ,3 ]
Aisner, Dara L. [3 ]
Doebele, Robert C. [2 ]
机构
[1] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[2] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, MS 8117,12801 E 17th Ave, Aurora, CO 80045 USA
[3] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
关键词
ROS1; KIT; NSCLC; Drug resistance; Tyrosine kinase inhibitor; Bypass signaling; C-KIT; TUMORS; ONCOGENE; FUSIONS;
D O I
10.1016/j.jtho.2016.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) chromosomal rearrangements benefit from treatment with the ROS1 inhibitor crizotinib. Limited data exist on the spectrum of resistance mechanisms in ROS1-positive NSCLC. To delineate mechanisms of acquired resistance, we analyzed biopsy samples of tumor lesions that progressed while patients were receiving crizotinib. Methods: An activating mutation in the KIT proto-oncogene receptor tyrosine kinase (KIT) (p.D816G) was identified by SNaPshot sequencing in a tumor sample from a patient with ROS1-positive NSCLC identified by fluorescence in situ hybridization whose disease progressed after initial response to crizotinib. In vitro studies included evaluation of KIT mRNA expression by quantitative reverse-transcriptase polymerase chain reactions, transduction of Ba/F3 cells and NSCLC cell lines with KIT-expressing lentiviral plasmids, immunoblotting, and cellular proliferation assays. Results: KITD816G is an activating mutation that induces autophosphorylation and cell proliferation. Expression of the mutant KITD816G receptor in ROS1-positive NSCLC cell lines led to constitutively activated KIT as measured by phosphorylation of the KIT receptor. Expression of the KITD816G rendered the HCC78 and CUTO2 cell lines resistant to crizotinib, and only dual inhibition of ROS1 and KIT with crizotinib and ponatinib could resensitize the cells to inhibition of proliferation. The oncogenic switch observed in ROS1-positive cell lines was not immediate and required pharmacologic inactivation of ROS1. Conclusions: Activation of KIT by a gain-of-function somatic mutation is a novel mechanism of resistance to crizotinib in ROS1-rearranged NSCLC. This bypass signaling pathway serves as a ROS1-independent mechanism of resistance, similarly to previously identified epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene homolog/neuroblastoma RAS viral oncogene homolog signaling pathways, and can potentially be targeted by KIT inhibitors. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1273 / 1281
页数:9
相关论文
共 50 条
  • [31] Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data
    Tremblay, Gabriel
    Groff, Michael
    Iadeluca, Laura
    Daniele, Patrick
    Wilner, Keith
    Wiltshire, Robin
    Bartolome, Lauren
    Usari, Tiziana
    Cappelleri, Joseph C.
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (17) : 2063 - 2074
  • [32] Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).
    Goto, Koichi
    Yang, James Chih-Hsin
    Kim, Dong-Wan
    Lu, Shun
    Seto, Takashi
    Yang, Jin-Ji
    Yamamoto, Noboru
    Ahn, Myung-Ju
    Takahashi, Toshiaki
    Yamanaka, Takeharu
    Kemner, Allison Margaret
    Roychowdhury, Debasish
    Paolini, Jolanda
    Wilner, Keith D.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] A SECONDARY ROS1 MUTATION CONFERS CRIZOTINIB RESISTANCE
    不详
    CANCER DISCOVERY, 2013, 3 (07) : 718 - 718
  • [35] Lorlatinib in ROS1-positive NSCLC
    David Killock
    Nature Reviews Clinical Oncology, 2020, 17 (1) : 7 - 7
  • [36] Outcomes of ROS1 positive metastatic lung cancer patients treated with crizotinib
    Dogan, I.
    Khanmammadov, N.
    Paksoy, N.
    Ferhatoglu, F.
    Aydin, E.
    Vatansever, S.
    Saip, P.
    Aydiner, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S782 - S782
  • [37] Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
    Katayama, Ryohei
    Kobayashi, Yuka
    Friboulet, Luc
    Lockerman, Elizabeth L.
    Koike, Sumie
    Shaw, Alice T.
    Engelman, Jeffrey A.
    Fujita, Naoya
    CLINICAL CANCER RESEARCH, 2015, 21 (01) : 166 - 174
  • [38] Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial
    Moro-Sibilot, D.
    Cozic, N.
    Pero, M.
    Mazieres, J.
    Otto, J.
    Souquet, P. J.
    Bahleda, R.
    Wislez, M.
    Zalcman, G.
    Guibert, S. D.
    Barlesi, F.
    Mennecier, B.
    Monnet, I
    Sabatier, R.
    Bota, S.
    Dubos, C.
    Verriele, V.
    Haddad, V
    Ferretti, G.
    Cortot, A.
    De Fraipont, F.
    Jimenez, M.
    Hoog-Labouret, N.
    Vassal, G.
    ANNALS OF ONCOLOGY, 2019, 30 (12) : 1985 - 1991
  • [39] Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
    Franke, A.
    Nair, V.
    Shafique, M.
    Mokhtari, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S858 - S859
  • [40] Crizotinib in ROS1-positive non-small cell lung cancer: an Asian large phase II trial confirms its key-role
    Maione, Paolo
    Gridelli, Cesare
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S792 - S795